|Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth|
D Drygin, A Lin, J Bliesath, CB Ho, SE O'Brien, C Proffitt, M Omori, ...
Cancer research 71 (4), 1418-1430, 2011
|Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53|
MJ Bywater, G Poortinga, E Sanij, N Hein, A Peck, C Cullinane, M Wall, ...
Cancer cell 22 (1), 51-65, 2012
|The nucleolus: an emerging target for cancer therapy|
N Hein, KM Hannan, AJ George, E Sanij, RD Hannan
Trends in molecular medicine 19 (11), 643-654, 2013
|UBF levels determine the number of active ribosomal RNA genes in mammals|
E Sanij, G Poortinga, K Sharkey, S Hung, TP Holloway, J Quin, E Robb, ...
The Journal of cell biology 183 (7), 1259-1274, 2008
|Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma|
O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell, ...
Nature communications 9 (1), 3970, 2018
|Dysregulation of RNA polymerase I transcription during disease|
KM Hannan, E Sanij, LI Rothblum, RD Hannan, RB Pearson
Biochimica Et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1829 (3-4 …, 2013
|First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study|
A Khot, N Brajanovski, DP Cameron, N Hein, KH Maclachlan, E Sanij, ...
Cancer discovery 9 (8), 1036-1049, 2019
|c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation|
G Poortinga, M Wall, E Sanij, K Siwicki, J Ellul, D Brown, TP Holloway, ...
Nucleic acids research 39 (8), 3267-3281, 2011
|The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin|
E Sanij, RD Hannan
Epigenetics 4 (6), 374-382, 2009
|Epstein-Barr virus LMP1 blocks p16INK4a–RB pathway by promoting nuclear export of E2F4/5|
N Ohtani, P Brennan, S Gaubatz, E Sanij, P Hertzog, E Wolvetang, ...
The Journal of cell biology 162 (2), 173-183, 2003
|Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy|
J Kang, N Brajanovski, KT Chan, J Xuan, RB Pearson, E Sanij
Signal Transduction and Targeted Therapy 6 (1), 323, 2021
|Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma|
JR Devlin, KM Hannan, N Hein, C Cullinane, E Kusnadi, PY Ng, ...
Cancer discovery 6 (1), 59-70, 2016
|ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway|
EJ Wolvetang, TJ Wilson, E Sanij, J Busciglio, T Hatzistavrou, A Seth, ...
Human molecular genetics 12 (3), 247-255, 2003
|CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer|
E Sanij, KM Hannan, J Xuan, S Yan, JE Ahern, AS Trigos, N Brajanovski, ...
Nature communications 11 (1), 2641, 2020
|Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling|
J Quin, KT Chan, JR Devlin, DP Cameron, J Diesch, C Cullinane, J Ahern, ...
Oncotarget 7 (31), 49800, 2016
|Conditional inactivation of Upstream Binding Factor reveals its epigenetic functions and the existence of a somatic nucleolar precursor body|
N Hamdane, VY Stefanovsky, MG Tremblay, A Nemeth, E Paquet, ...
PLoS genetics 10 (8), e1004505, 2014
|Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells|
J Diesch, E Sanij, O Gilan, C Love, H Tran, NI Fleming, J Ellul, M Amalia, ...
PloS one 9 (3), e88950, 2014
|Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma|
S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ...
Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019
|Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers|
M Udugama, E Sanij, HPJ Voon, J Son, L Hii, JD Henson, FL Chan, ...
Proceedings of the National Academy of Sciences 115 (18), 4737-4742, 2018
|Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population|
N Hein, DP Cameron, KM Hannan, NYN Nguyen, CY Fong, J Sornkom, ...
Blood, The Journal of the American Society of Hematology 129 (21), 2882-2895, 2017